FDA Philippines advisories on GLP-1s and peptides

As of 14 November 2026, this timeline lists 11 FDA Philippines public health warnings naming a GLP-1 medicine, a peptide or bacteriostatic water, the latest dated 6 October 2026 (retatrutide). Each is a warning against an unregistered product. No advisory found names Ozempic, Wegovy, Mounjaro or BPC-157.

• 6 October 2026, FDA Advisory No. 2026-1392. The FDA warned the public against buying or using the unregistered drug product Retatrutide 30 mg lyophilized powder for injection, which has no Certificate of Product Registration. Read the advisory
• 26 September 2026, FDA Advisory No. 2026-1265. The FDA warned the public against buying or using the unregistered drug product Retatrutide 30 mg lyophilized powder for injection, which has no Certificate of Product Registration. Read the advisory
• 4 September 2026, FDA Advisory No. 2026-1019. The FDA warned the public against buying or using the unregistered drug product Peptatide Tirzepatide 15mg sold with Peptatide bacteriostatic water, which has no Certificate of Product Registration. Read the advisory
• 4 September 2026, FDA Advisory No. 2026-1020. The FDA warned the public against buying or using an unregistered 30 mg multi-use tirzepatide vial sold with bacteriostatic water, which has no Certificate of Product Registration. Read the advisory
• 4 September 2026, FDA Advisory No. 2026-1013. The FDA warned the public against buying or using an unregistered KPV 10 mg/1 ml multi-use injectable vial sold with bacteriostatic water, which has no Certificate of Product Registration. Read the advisory
• 30 July 2026, FDA Advisory No. 2026-0814. The FDA warned the public against buying or using the unregistered drug product Tirz Laine Tirzepatide 30mg/3 mL 99% Purity, which has no Certificate of Product Registration. Read the advisory
• 5 June 2026, FDA Advisory No. 2026-0622. The FDA warned the public against buying or using Pepslim Bacteriostatic Water 3mL Vial, an unregistered drug product with no Certificate of Product Registration. Read the advisory
• 4 May 2026, FDA Advisory No. 2026-0596. FDA Philippines published updates to its list of VAT-exempt drugs and medicines under the CREATE Act, listing tirzepatide solutions for subcutaneous injection under medicines for diabetes. Read the advisory
• 23 February 2026, FDA Advisory No. 2026-0065. The FDA published updates to the list of VAT-exempt health products, which include tirzepatide 2.5 mg to 15 mg per 0.6 mL solution for injection for diabetes. Read the advisory
• 6 November 2025, FDA Advisory No. 2025-1200. The FDA published updates to the list of VAT-exempt health products, which include semaglutide products. Read the advisory
• 30 January 2025, FDA Advisory No. 2025-0084. FDA Philippines warned the public against buying or consuming an unregistered liposomal NAD+ food supplement in capsules, for which no Certificate of Product Registration had been issued. Read the advisory
• 2 October 2024, FDA Advisory No. 2024-1352. The FDA warned the public against buying or using five unregistered drug products, including a thymopolypeptide tablet, that had not been issued a Certificate of Product Registration. Read the advisory
• 20 March 2024, FDA Advisory No. 2024-0535. The FDA warned the public against buying or using four unregistered drug products, including Saxenda 3mL x 5 pre-filled pens, that had not been issued a Certificate of Product Registration. Read the advisory
• 23 February 2024, FDA Advisory No. 2024-0328. The FDA warned the public against buying or using five unregistered injectable drug products, including LG Chem Declage recombinant hGH (somatropin) 3 mg. Read the advisory

• Eli Lilly and Company, 20 June 2024. Lilly stated that counterfeit and untested compounded products sold as tirzepatide may contain no medicine, the wrong medicine or incorrect doses, and that some compounded products it found contained bacteria or high impurity levels. Source
• Eli Lilly and Company, 12 August 2026. Lilly stated that retatrutide is an investigational molecule in phase 3 trials, that no retatrutide medicine is approved anywhere, and that it has sued US sellers that label retatrutide products research-use only while intending them for human use. Source
• Novo Nordisk A/S, undated web page (copyright 2026). Novo Nordisk states that it is the sole manufacturer of approved semaglutide medicines (Wegovy, Ozempic and Rybelsus) and that its testing found compounded samples with lower strength, no semaglutide, or added impurities. Source
• Novo Nordisk A/S, undated web page. Novo Nordisk describes falsified medicines as deliberately mislabelled products whose contents are unknown and asks the public to report suspected falsified Novo Nordisk products to the company in their country. Source

Advisories were read on the FDA Philippines site or through the FDA verification portal, which serves the same posts. The list merges this site's own search with the advisory dataset our partner and supplier publishes, deduplicated by advisory number. Attached PDFs were not searched, so an advisory that names a product only in an attachment may be missing.

• Are peptides legal in the Philippines?
• How FDA Philippines registration works, and what "not registered" means
• Prescription rules for GLP-1 medicines
• Bringing medicines or peptides into the Philippines
• Is selling peptides legal in the Philippines?
• Regulatory status by compound

Sources checked 23 September 2026. Primary sources only: statutes, DOH and FDA Philippines issuances, the FDA verification portal and the Bureau of Customs. This is general information, not legal advice.